[Your role / profession]
- A Computer Engineering student and aspiring AI/ML researcher deeply interested in longevity science, aging biology, healthspan extension, and the application of artificial intelligence to aging research
[Keep]
- Major new research findings on the biology and mechanisms of aging
- Clinical trial results involving interventions targeting aging or age-related biological processes
- Breakthroughs in partial cellular reprogramming, epigenetic rejuvenation, senolytics, rapamycin, NAD+ metabolism, gene therapy, and regenerative medicine
- Research on biological age, epigenetic clocks, aging biomarkers, and multi-omics approaches including genomics, transcriptomics, proteomics, and methylation
- Advances in AI/ML specifically applied to aging biology mechanisms, biological age prediction models, longevity drug discovery, or geroscience research (not general disease diagnostics)
- Important datasets, computational tools, models, or open-source projects relevant to aging biology and longevity research
- News from major longevity companies, research labs, startups, and prominent researchers
- FDA approvals, major clinical milestones, significant funding rounds, or major partnerships related to longevity biotechnology
- High-quality systematic reviews, meta-analyses, and landmark papers on aging and longevity interventions
- Major discoveries related to lifespan extension, healthspan improvement, cellular senescence, age-related diseases, and mechanisms of rejuvenation
[Filter out]
- Generic wellness, diet, exercise, or lifestyle advice without strong scientific relevance to aging research
- Marketing content for supplements, anti-aging products, or treatments without solid clinical evidence
- Celebrity anti-aging routines, beauty industry news, skincare trends, or cosmetic procedures
- Sensationalized longevity claims without credible scientific evidence
- Low-quality studies, press releases that exaggerate findings, or purely speculative anti-aging content
- Diagnostic tools, imaging platforms, or AI applications for age-related diseases (e.g. Alzheimer's, cancer) that focus on detection/diagnosis rather than aging mechanisms or longevity interventions
Filter Strictness80
Translate To
Sources (3)
We support more dynamic and UGC websites now. If a source fails to crawl, please let us know on Discord.
Deepinder Goyal’s brain-wearable startup, Temple, has acquired Longevous. Longevous cofounders Dr Robert Mohr and Dr Avi Roy will join Temple in full-time roles to steer the science.
Next Generation Longevity 2026 (NGL 2026) will convene at Nakanoshima Qross in Osaka, Japan, on 15–16 October. The two-day meeting will bring together clinicians, researchers, founders, technologists, and investors to examine how longevity medicine can move from a body of knowledge into clinical and…
Phil Newman, Paola Telfer (CEO of Sens.ai), and Eric Verdin (CEO of the Buck Institute for Research on Aging) discuss BrainYears™, a functional brain age clock designed to measure brain performance during aging. The model uses machine learning to analyze 643 EEG, response, and performance variables,…
On June 16, 2026, the United States Patent and Trademark Office issued U.S. Patent No. 12,653,907 to BioViva USA Inc. titled "Methods of Treating or Preventing Age-Related Disorders." The patent covers therapeutic methods combining human telomerase reverse transcriptase (hTERT) and Follistatin-344 (…
Resolution Therapeutics has completed enrollment in its Phase I/II EMERALD study of RTX001 for patients with end-stage liver disease and prior hepatic decompensation. Fifteen patients were dosed with RTX001, an engineered regenerative macrophage therapy incorporating IL-10 and MMP-9 to address infla…
Sam Altman-backed Retro Biosciences is expanding its trial for RTR-242, a pill designed to clear cellular junk from the brain associated with age and conditions like Alzheimer’s and Parkinson’s, after early doses showed no red flags.
Outer Bio’s Yuna platform keeps living human skin functioning for a month, providing scientists with a longer window to test compounds that slow visible aging compared to the few days skin typically lasts outside the body.
A SIRT6 gene therapy trial in senior beagles conducted by UK biotech Genflow Bios met its primary endpoint, lowering biological age. The trial serves as a potential test bed for human medicine because aging dogs share similar environments and age-related conditions with humans.